Victoza Pancreatic Cancer Lawsuit

Victoza, Januvia and Byetta are members of the “incretin mimetic” class of drugs used to treat type 2 Diabetes. They work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal.

Victoza Has Been Linked to Pancreatic Cancer

In February 2013, the journal Jama International Medicine published an analysis of insurance records showing that use of Victoza and other incretin mimetics can double the risk of developing pancreatitis, a condition that can lead to pancreatic cancer.

The FDA is reviewing unpublished data linking Victoza and the other type 2 Diabetes drugs in the incretin mimetic class to pancreatic cancer.

Pancreatic Cancer Victims Are Filing Lawsuits

Many lawsuits claiming that Victoza caused pancreatic cancer are currently pending in federal courts around the country. The Judicial Panel on Multidistrict Litigation has considered consolidating them into a multidistrict litigation action (an “MDL”), which would streamline the pretrial discovery phase of many Victoza pancreatic cancer cases while still allowing the cases to be tried separately.

Victoza Jury Awards and Settlements

At present, there has not been any compensation awarded to Victoza plaintiffs by juries, nor has there been word of Victoza settling out-of-court with any plaintiffs. Typically, personal injury lawsuits take about two years to reach the trial phase of litigation after they are filed. As the number of Victoza pancreatic cancer plaintiffs increases, Victoza’s manufacturer might consider an attempt at settling with some of them, but so far, there has not been any announcement of a settlement offer from that drug maker.

  • By submitting this form, you give RLG permission to contact you privately. Privacy policy.
  • This field is for validation purposes and should be left unchanged.